WOBURN, Mass.--(BUSINESS WIRE)--Aeris Therapeutics, LLC announced that the U.S. Patent and Trademark Office has issued a patent covering the use of cross-linked polymers administered into the lung to reduce lung volume for the treatment of emphysema. This newly issued patent, entitled “Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers,” covers novel technology that enables lung volume reduction therapy without high risk surgery.
